Skip to main content

Corbus Pharmaceuticals Holdings, Inc.

CRBP
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001595097

In the last 90 days, Corbus Pharmaceuticals Holdings, Inc. insiders filed 1 open-market purchase and 3 sales; 107 institutions reported holding it in 13F filings for Q2 2026, worth $129.1M in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Corbus Pharmaceuticals Holdings, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
1 filing
1 insider, $25.0K in total
Open-market sells
3 filings
3 insiders, $308.0K in total
Insiders trading
4
Net value
−$283.0K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Corbus Pharmaceuticals Holdings, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Corbus Pharmaceuticals Holdings, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Ben YongDirector9,383Sep 15, 20262
Nicacio Leonardo VianaChief Medical Officer58,333Aug 17, 20261
Saxena Nishant CChief Business Officer77,900Aug 12, 20263
Cohen YuvalChief Executive Officer157,316Aug 10, 20264
Moran Sean F.Chief Financial Officer84,694Aug 10, 20264
Kung WinstonDirector12,140Jun 11, 20262
Jenkins John KennethDirector3,833Jun 11, 20262
Altmeyer AnneDirector7,579Jun 11, 20263
Jacques Rachelle SuzanneDirector11,383May 21, 20261
Pfeiffenberger BrentDirector7,500May 21, 20261
Smethurst DominicChief Medical Officer89,790Mar 4, 20263
Hodgson IanChief Operating Officer51,080Feb 18, 20263
Cormorant Asset Management, LP10% Owner2,344,971IndirectDec 15, 20251
Chen Bihua10% Owner2,344,971IndirectDec 15, 20251
Cormorant Global Healthcare Master Fund, LP10% Owner2,344,971IndirectDec 15, 20251
Holmer Alan FDirector10,629Jun 2, 20250
Catlin Avery WDirector4,350Jun 3, 20240
Salzmann PeterDirector2,783Jun 3, 20240
Millian Craig StuartChief Operating Officer27,000Feb 15, 20230
Brake Rachael LouiseChief Scientific Officer–Feb 15, 20230

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Sep 15, 2026 (view filing)4:59 PM ETSep 141 dayBen YongDirectorSSaleCommon Stock, par value $0.0001 per share−2.00K$7.84−$15.7K−17.6%9.38K after10b5-1
Aug 12, 2026 (view filing)4:30 PM ETAug 111 daySaxena Nishant CChief Business OfficerPPurchaseCommon Stock, par value $0.0001 per share+2.60K$9.63+$25.0K+3.5%77.9K after
Aug 10, 2026 (view filing)4:30 PM ETAug 73 daysCohen YuvalChief Executive OfficerSSaleCommon Stock, par value $0.0001 per share−17.0K$10.08−$171.4K−9.8%157.3K after10b5-1
Aug 10, 2026 (view filing)4:30 PM ETAug 73 daysMoran Sean F.Chief Financial OfficerSSaleCommon Stock, par value $0.0001 per share−12.0K$10.08−$121.0K−12.4%84.7K after10b5-1
Jun 11, 2026 (view filing)Jun 101 dayKung WinstonDirectorSSaleCommon Stock, par value $0.0001 per share−2.03K$7.91−$16.0K−14.3%12.1K after10b5-1
Jun 11, 2026 (view filing)Jun 101 dayJenkins John KennethDirectorSSaleCommon Stock, par value $0.0001 per share−4.80K$7.91−$38.0K−55.6%3.83K after10b5-1
Jun 11, 2026 (view filing)Jun 101 dayAltmeyer AnneDirectorSSaleCommon Stock, par value $0.0001 per share−2.41K$7.91−$19.1K−24.1%7.58K after10b5-1
Jun 3, 2026 (view filing)Jun 2-31 daySaxena Nishant CChief Business OfficerPPurchaseCommon Stock, par value $0.0001 per share+13.5K$7.50+$101.2K+21.8%75.3K after2 lots
Mar 4, 2026 (view filing)Mar 22 daysSmethurst DominicChief Medical OfficerSSaleCommon Stock, par value $0.0001 per share−6.10K$8.30−$50.6K−6.4%89.8K after
Feb 18, 2026 (view filing)Feb 171 dayHodgson IanChief Operating OfficerSSaleCommon Stock, par value $0.0001 per share−847$7.38−$6.25K−1.6%51.1K after
Feb 18, 2026 (view filing)Feb 135 daysMoran Sean F.Chief Financial OfficerSSaleCommon Stock, par value $0.0001 per share−4.70K$7.78−$36.6K−4.6%96.7K after10b5-1
Feb 18, 2026 (view filing)Feb 135 daysCohen YuvalChief Executive OfficerSSaleCommon Stock, par value $0.0001 per share−13.9K$7.78−$107.9K−7.4%174.3K after10b5-1
Feb 4, 2026 (view filing)Feb 31 daySmethurst DominicChief Medical OfficerSSaleCommon Stock, par value $0.0001 per share−3.29K$8.09−$26.6K−3.3%95.9K after
Feb 4, 2026 (view filing)Feb 31 dayHodgson IanChief Operating OfficerSSaleCommon Stock, par value $0.0001 per share−2.42K$8.09−$19.5K−4.4%51.9K after
Dec 15, 2025 (view filing)4:18 PM ETDec 114 daysCormorant Asset Management, LP and 2 others10% OwnerSSale−30.0K$11.46−$344.0K−1.3%2.34M after
Oct 27, 2025 (view filing)Oct 24-273 daysCohen YuvalChief Executive OfficerSSaleCommon Stock, par value $0.0001 per share−27.6K$17.05−$471.2K−16.7%138.2K after2 lots10b5-1
Oct 27, 2025 (view filing)Oct 243 daysMoran Sean F.Chief Financial OfficerSSaleCommon Stock, par value $0.0001 per share−13.0K$17.02−$220.9K−15.0%73.3K after10b5-1
Oct 21, 2025 (view filing)Oct 201 dayAltmeyer AnneDirectorSSaleCommon Stock, par value $0.0001 per share−1.06K$20.50−$21.7K−14.6%6.19K after10b5-1
Jun 2, 2025 (view filing)May 303 daysJenkins John KennethDirectorSSaleCommon Stock, par value $0.0001 per share−2.78K$7.35−$20.5K−98.8%33 after10b5-1
Jun 2, 2025 (view filing)May 303 daysAltmeyer AnneDirectorSSaleCommon Stock, par value $0.0001 per share−1.39K$7.25−$10.1K−50.0%1.39K after10b5-1
Mar 7, 2025 (view filing)Mar 61 daySmethurst DominicChief Medical OfficerSSaleCommon Stock, par value $0.0001 per share−6.39K$6.78−$43.3K−8.3%70.8K after
Feb 18, 2025 (view filing)Feb 144 daysMoran Sean F.Chief Financial OfficerSSaleCommon Stock, par value $0.0001 per share−2.79K$8.76−$24.5K−3.7%73.3K after10b5-1
Feb 18, 2025 (view filing)Feb 144 daysCohen YuvalChief Executive OfficerSSaleCommon Stock, par value $0.0001 per share−7.13K$8.76−$62.5K−4.9%138.2K after10b5-1
Sep 24, 2024 (view filing)4:04 PM ETSep 204 daysCormorant Asset Management, LP and 2 others10% OwnerPPurchase+350.0K$20.01+$7.00M+17.3%2.38M after6 lots
Jun 18, 2024 (view filing)Jun 14-184 daysMoran Sean F.Chief Financial OfficerSSaleCommon Stock, par value $0.0001 per share−18.0K$47.87−$863.8K−27.1%48.6K after4 lots10b5-1
Jun 18, 2024 (view filing)Jun 14-184 daysCohen YuvalChief Executive OfficerSSaleCommon Stock, par value $0.0001 per share−63.4K$46.57−$2.95M−45.1%77.2K after8 lots10b5-1
Mar 11, 2024 (view filing)5:34 PM ETMar 7-84 daysCormorant Asset Management, LP and 2 others10% OwnerPPurchase+550.0K$42.41+$23.3M+37.3%2.02M after10 lots
Feb 6, 2024 (view filing)4:00 PM ETFeb 24 daysCormorant Asset Management, LP and 2 others10% OwnerPPurchase+750.0K$19.00+$14.3M+103.4%1.48M after
Jan 30, 2024 (view filing)4:23 PM ETJan 264 daysCormorant Asset Management, LP and 2 others10% OwnerPPurchase+282.6K$32.24+$9.11M+63.9%725.0K after14 lots
Aug 12, 2022 (view filing)9:43 AM ETAug 102 daysMillian Craig StuartChief Operating OfficerPPurchase+5.00K$0.2545+$1.27K+22.7%27.0K after
Aug 11, 2022 (view filing)9:55 AM ETAug 101 dayCohen YuvalChief Executive OfficerPPurchase+3.80K$0.264+$1.00K+4.0%98.2K after
Aug 10, 2022 (view filing)10:16 AM ETAug 10Same dayMoran Sean F.Chief Financial OfficerPPurchase+20.0K$0.2599+$5.20K+11.2%199.3K after
May 16, 2022 (view filing)11:03 AM ETMay 16Same dayMoran Sean F.Chief Financial OfficerPPurchase+12.0K$0.30+$3.60K+7.2%179.3K after
May 16, 2022 (view filing)10:41 AM ETMay 16Same dayCohen YuvalChief Executive OfficerPPurchase+10.5K$0.25+$2.63K+12.5%94.4K after
Mar 11, 2022 (view filing)11:23 AM ETMar 101 dayMillian Craig StuartChief Operating OfficerPPurchase+10.0K$0.37+$3.70K+83.3%22.0K after
Mar 10, 2022 (view filing)11:47 AM ETMar 10Same dayMoran Sean F.Chief Financial OfficerPPurchase+15.0K$0.37+$5.55K+9.9%167.3K after
Mar 9, 2022 (view filing)10:37 AM ETMar 9Same dayCohen YuvalChief Executive OfficerPPurchase+8.60K$0.37+$3.18K+11.4%83.9K after